April 13, 2026
01
Enviro Infra Engineers zooms 11.91% — bags ₹972 crore Maharashtra sewage contracts
Mega Order Win
Enviro Infra Engineers secured two major Letters of Empanelment from the Swachh Maharashtra Mission Directorate. Project 1: ₹587.20 crore for 120.50 MLD STP with 209 KM I&D and 887 KM sewer network across 306 urban bodies. Project 2: ₹384.98 crore for 121.10 MLD STP with 105.5 KM I&D and 433 KM sewer network. Both projects are EPC-basis with 24-month execution timelines under Swachh Bharat Mission Urban 2.0.
CMP
₹194.00
Change
+₹20.65 (+11.91%)
Day high/low
₹198.65 / ₹185.05
52W high
₹306.30
52W low
₹135.00
Market cap
₹3,453 Cr
BSE Group AFace Value ₹10Mid Cap
Promoters 70.13%Institutions 1.43%Non-Inst 28.44%
02
GHV Infra Projects bags ₹1,250 crore expressway contract from APCO Infratech
Major Construction Contract
GHV Infra Projects signed a landmark construction contract with APCO Infratech for development of expressway connectors from Jalna to Nanded, Maharashtra. The contract, valued at ₹1,250 crore (ex-taxes), covers survey & investigation, design, engineering, procurement, construction, supply of plant & materials and maintenance. Construction period is 30 months. At ₹2,335 crore market cap, this single order represents ~54% of market cap — a very strong order book addition.
CMP
₹316.00
Change
+₹6.50 (+2.10%)
Day high/low
₹324.95 / ₹310.00
52W high
₹368.50
52W low
₹70.85
Market cap
₹2,335 Cr
BSE Group XTFace Value ₹5Small-Mid Cap
Promoters 70.41%Non-Inst 29.59%
03
Coforge rises — all regulatory clearances secured for ₹multi-crore Encora acquisition
Acquisition Milestone
Coforge secured all regulatory approvals and statutory clearances across multiple jurisdictions for the acquisition of Encora, an AI-native engineering services firm serving Fortune 1000 companies. Key highlights: all senior leaders retained; G&A cost optimisation plan targeting 20%–25% reduction in combined business costs; integration milestones on track; commercial & sales teams of both firms ready for immediate collaborative operations post-closing. Encora acquisition was signed in December 2025.
CMP
₹1,228.30
Change
+₹4.25 (+0.35%)
Day high/low
₹1,231 / ₹1,200
52W high
₹1,994.00
52W low
₹1,008.50
Market cap
₹41,194 Cr
BSE Group AFace Value ₹2Large Cap
Institutions 88.20%Non-Inst 11.80%
04
HUDCO gains 1.47% — signs two MoUs with NBCC for New Delhi redevelopment
MoU / Collaboration
HUDCO signed two MoUs with NBCC (India) on April 11, 2026, for collaborative redevelopment of an 18,830 sq.m. leasehold plot at August Kranti Bhawan, Bhikaji Cama Place, New Delhi. Scope covers techno-economic feasibility, construction & project management, and monetisation of built-up space. HUDCO will fund NBCC's self-sustainable model projects with Government of India approval; NBCC will provide Project Management and consultancy services. Strong 75% promoter holding (GoI-backed PSU).
CMP
₹186.70
Change
+₹2.70 (+1.47%)
Day high/low
₹186.75 / ₹177.60
52W high
₹253.80
52W low
₹158.95
Market cap
₹37,385 Cr
BSE Group AFace Value ₹10Large Cap PSU
Promoters (GoI) 75%Institutions 13.25%Non-Inst 11.74%
05
AstraZeneca Pharma surges 1.45% — CDSCO nod to market Calquence (Acalabrutinib) for blood cancer
Regulatory Approval
AstraZeneca Pharma India received CDSCO permission to import, sell and distribute Acalabrutinib 100 mg tablets (brand: Calquence) for an additional indication — treatment of previously untreated Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL) in combination with venetoclax ± obinutuzumab. This opens a new oncology market in India for a globally approved therapy. Promoter holding is a strong 75% (AstraZeneca PLC UK). Market cap at ₹20,877 Cr.
CMP
₹8,172.85
Change
-₹118.65 (-1.43%)*
Day high/low
₹8,443 / ₹8,002
52W high
₹10,653.05
52W low
₹7,630.00
Market cap
₹20,877 Cr
*Data note: source reports +1.45% but CMP vs prev close shows decline — please verify on exchange.
BSE Group AFace Value ₹2Large Cap MNC
Promoters 75%Institutions 8.26%Non-Inst 16.74%
06
Piramal Pharma gains 0.51% — USFDA issues EIR with VAI for Kentucky manufacturing facility
USFDA Clearance
Piramal Pharma received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) from the USFDA for its Lexington, Kentucky facility — the cleanest possible inspection outcome, marking successful closure. VAI status means no regulatory action required and the facility can continue supplying US markets without interruption. This boosts confidence in Piramal's CDMO capabilities for regulated US market supply.
CMP
₹146.85
Change
+₹0.75 (+0.51%)
Day high/low
₹147.45 / ₹140.85
52W high
₹228.45
52W low
₹132.50
Market cap
₹19,560 Cr
BSE Group AFace Value ₹10Mid Cap
Promoters 34.86%Institutions 45.35%Non-Inst 19.79%
07
Heranba Industries jumps 5.37% — enters crop nutrition with two bio-products (US collaboration)
New Segment Entry
Heranba Industries made a strategic entry into crop nutrition by launching two innovative products developed with a leading American multinational: Fentaamine — a next-gen bio stimulant enhancing plant metabolism, stress tolerance & yield; and MycoHil — an advanced biofertilizer improving nutrient absorption and soil microbiology. Both target India and global markets, marking a meaningful pivot beyond pesticides toward sustainable agri-inputs.
CMP
₹203.00
Change
+₹10.35 (+5.37%)
Day high/low
₹206.85 / ₹188.00
52W high
₹403.40
52W low
₹155.80
Market cap
₹794 Cr
BSE Group BFace Value ₹10Small Cap
Promoters 74.94%Institutions 0.15%Non-Inst 24.91%
08
Modern Engineering zooms 9.44% — bags ₹60 crore Tata Steel road order (Neelachal expansion)
Order Win
Modern Engineering and Projects received a ₹60 crore work order from Tata Steel for construction of a Priority Bituminous Trunk Road for the Neelachal Ispat Nigam (NINL) expansion project. The order is to be executed in approximately one year. At ₹56.95 crore market cap, the order is larger than its entire market capitalisation — a very significant win for this micro-cap company.
CMP
₹36.99
Change
+₹3.19 (+9.44%)
Day high/low
₹39.30 / ₹35.55
52W high
₹49.89
52W low
₹24.79
Market cap
₹56.95 Cr
BSE Group XFace Value ₹10Micro Cap
Promoters 33.29%Institutions 7.24%Non-Inst 59.47%
09
Panacea Biotec rises 1.07% — LoA of ₹20.79 crore from Govt of India for Td vaccine supply
Government Order
Panacea Biotec received a Letter of Award from Central Medical Services Society (CMSS), Ministry of Health & Family Welfare, GoI, worth ₹20.79 crore for supply of Diphtheria & Tetanus Vaccine (Td Vaccine) for Adults & Adolescents in multiple tranches. Supply period: September/October 2026 to November/December 2028. This reinforces Panacea's government vaccine supply credentials and revenue visibility.
CMP
₹329.50
Change
+₹3.50 (+1.07%)
Day high/low
₹330.90 / ₹314.35
52W high
₹581.00
52W low
₹293.10
Market cap
₹1,962 Cr
BSE Group BFace Value ₹1Small Cap
Promoters 72.48%Institutions 3.21%Non-Inst 24.31%
10
NCL Industries surges 1.30% — cement production grows 2% to 8.03 lakh MT in Q4FY26
Production Data
NCL Industries reported Q4FY26 cement production of 8,02,600 MT (+2% YoY) and dispatches of 8,04,813 MT (+1% YoY). Full-year FY26 cement production: 27.68 lakh MT. However, the quarter showed mixed signals: cement boards production crashed 51% YoY to 10,164 MT; dispatches fell 22%; RMC production down 5%; Door production down 100% YoY to just 20 units. The diversified building materials business faces headwinds outside core cement.
CMP
₹183.50
Change
+₹2.35 (+1.30%)
Day high/low
₹183.50 / ₹176.85
52W high
₹239.20
52W low
₹147.65
Market cap
₹830 Cr
BSE Group BFace Value ₹10Small Cap
Promoters 40.95%Institutions 4.13%Non-Inst 54.93%
11
Baazar Style Retail trades up 0.22% — opens 3 new stores, reaches 270 store network
Expansion
Baazar Style Retail expanded its footprint with 3 new store openings in 2 days: 2 Style Baazar stores at Rai Bareli Road (UP) and Axis Mall (West Bengal) on April 11; 1 Express Baazar at Balasore, Odisha on April 12. Total store count now stands at 270. The value retail chain targets Tier 2/3 markets. Despite the expansion momentum, the stock is trading significantly below its 52W high of ₹391.90, suggesting the market awaits profitability scale-up.
CMP
₹293.00
Change
+₹0.65 (+0.22%)
Day high/low
₹293.70 / ₹281.80
52W high
₹391.90
52W low
₹230.00
Market cap
₹2,177 Cr
BSE Group BFace Value ₹5Small Cap
Promoters 45.71%Institutions 11.05%Non-Inst 43.24%
12
Veerhealth Care rises 1.85% — bags $1,60,650 export order from New York company
Export Order
Veerhealth Care received an export order from a New York-based company for supply of body care products worth $1,60,650 (~₹1.50 crore), to be completed in 45 days. While the order size is small relative to the company's size, it signals international market entry and the company anticipates additional growth in export turnover. Promoter holding at 31.50% is relatively low — majority held by retail investors (68.50%).
CMP
₹20.94
Change
+₹0.38 (+1.85%)
Day high/low
₹21.21 / ₹20.80
52W high
₹23.77
52W low
₹11.81
Market cap
₹41.12 Cr
BSE Group XFace Value ₹10Micro Cap
Promoters 31.50%Non-Inst 68.50%
SEBI Disclaimer — Strictly for Educational Purposes Only
This news bulletin is compiled strictly for educational and informational purposes only and does NOT constitute investment advice, a buy/sell recommendation, or a solicitation of any securities transaction. All data presented is sourced from publicly available exchange filings and news sources as of April 13, 2026, and is provided on an "as-is" basis without any warranty of accuracy or completeness. Investors are strongly advised to independently verify all data on BSE/NSE official websites before relying on it.
Stock markets are subject to market risks. Past performance is not indicative of future results. Prices, volumes, and market data are subject to real-time change. The publisher/author of this bulletin is NOT a SEBI-registered Research Analyst. This content does not constitute a Research Report under SEBI (Research Analysts) Regulations, 2014.
Please consult your SEBI-registered investment advisor, stockbroker, or financial planner before making any investment decisions. Read all scheme-related documents, financial statements, and exchange filings carefully before investing. Investments in securities markets are subject to market risks — please read all related documents carefully before investing.
Stock markets are subject to market risks. Past performance is not indicative of future results. Prices, volumes, and market data are subject to real-time change. The publisher/author of this bulletin is NOT a SEBI-registered Research Analyst. This content does not constitute a Research Report under SEBI (Research Analysts) Regulations, 2014.
Please consult your SEBI-registered investment advisor, stockbroker, or financial planner before making any investment decisions. Read all scheme-related documents, financial statements, and exchange filings carefully before investing. Investments in securities markets are subject to market risks — please read all related documents carefully before investing.